Gain Therapeutics, Inc. Common Stock GANX
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-06T17:39:23.316Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-12-18
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-06T17:38:45.07658568Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-06T17:39:21.542624+00:00
Gain Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | 1.07 | 471.0% | 55.2% | |||
| 30Δ | 1.13 | 445.5% | 51.1% | |||
| 35Δ | 1.20 | 420.0% | 47.1% | |||
| 40Δ | 1.27 | 394.4% | 43.0% | |||
| 45Δ | 1.34 | 368.9% | 38.9% | |||
| 50Δ | 1.41 | 343.4% | 34.8% | |||
| 55Δ | 1.48 | 317.9% | 30.7% | |||
| 60Δ | 1.55 | 292.3% | 26.6% | |||
| 65Δ | 1.62 | 266.8% | 22.5% | |||
| 70Δ | 1.69 | 241.3% | 18.4% | |||
| 75Δ | 1.76 | 215.7% | 14.3% | |||
| 80Δ | 1.26 | 539.1% | 90.4% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.07
- IV
- 471.0%
- B/E move
- 55.2%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.13
- IV
- 445.5%
- B/E move
- 51.1%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.20
- IV
- 420.0%
- B/E move
- 47.1%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.27
- IV
- 394.4%
- B/E move
- 43.0%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.34
- IV
- 368.9%
- B/E move
- 38.9%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.41
- IV
- 343.4%
- B/E move
- 34.8%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.48
- IV
- 317.9%
- B/E move
- 30.7%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.55
- IV
- 292.3%
- B/E move
- 26.6%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.62
- IV
- 266.8%
- B/E move
- 22.5%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.69
- IV
- 241.3%
- B/E move
- 18.4%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.76
- IV
- 215.7%
- B/E move
- 14.3%
80Δ
- Pseudo strike
- 1.26
- IV
- 539.1%
- B/E move
- 90.4%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 282.62% | |
| 234.70% | |
| 274.40% | |
| 299.20% | |
| 196.99% | |
| 188.48% | |
| 214.53% | |
| 213.81% | |
| 187.28% | |
| 199.30% | |
| 228.48% | |
| 296.02% | |
| 232.36% | |
| 272.03% | |
| 235.65% |
Biotechnology
GENB
Generate Biomedicines, Inc. is an innovative biotechnology company at the forefront of protein therapeutics development, leveraging advanced genetic engineering and artificial…
More →GERN
Geron Corporation, an advanced stage clinical biopharmaceutical company, focuses on the development and commercialization of therapies for myeloid hematologic neoplasms. The…
More →GHRS
GH Research PLC is a pioneering clinical-stage biopharmaceutical company focused on developing psilocybin-based therapies for psychiatric and neurodegenerative disorders. The…
More →GLUE
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, is dedicated to developing new precision small molecule drugs that employ the body's natural mechanisms to selectively…
More →GMAB
Genmab A / S develops antibody therapies for the treatment of cancer and other diseases mainly in Denmark. The company is headquartered in Copenhagen, Denmark.
More →GNLX
Description unavailable
More →